ScoreWhy is Swedish Orphan Biovitrum AB ?
1
Healthy long term growth as Net Sales has grown by an annual rate of 13.10%
2
With a growth in Net Profit of 72.48%, the company declared Very Positive results in Jun 26
- The company has declared positive results for the last 8 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at SEK 7,861 MM
- NET SALES(Q) Highest at SEK 7,842 MM
- PRE-TAX PROFIT(Q) At SEK 1,778 MM has Grown at 72.45%
3
With ROE of 19.82%, it has a expensive valuation with a 3.84 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 65.40%, its profits have risen by 96.5% ; the PEG ratio of the company is 0.2
4
Market Beating Performance
- The stock has generated a return of 65.40% in the last 1 year, much higher than market (OMX Stockholm 30) returns of 27.70%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Swedish Orphan Biovitrum AB should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Swedish Orphan Biovitrum AB for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Swedish Orphan Biovitrum AB
65.4%
95.11
28.04%
OMX Stockholm 30
27.7%
1.79
15.50%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
13.10%
EBIT Growth (5y)
12.54%
EBIT to Interest (avg)
7.83
Debt to EBITDA (avg)
1.86
Net Debt to Equity (avg)
0.33
Sales to Capital Employed (avg)
0.50
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.39%
ROE (avg)
10.77%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
3.84
EV to EBIT
20.12
EV to EBITDA
9.33
EV to Capital Employed
2.97
EV to Sales
5.98
PEG Ratio
0.20
Dividend Yield
NA
ROCE (Latest)
14.77%
ROE (Latest)
19.82%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
OPERATING CASH FLOW(Y)
Highest at SEK 7,861 MM
NET SALES(Q)
Highest at SEK 7,842 MM
PRE-TAX PROFIT(Q)
At SEK 1,778 MM has Grown at 72.45%
NET PROFIT(Q)
At SEK 1,373.42 MM has Grown at 66.43%
-2What is not working for the Company
INTEREST(Q)
At SEK 204 MM has Grown at 17.92%
Here's what is working for Swedish Orphan Biovitrum AB
Operating Cash Flow
Highest at SEK 7,861 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (SEK MM)
Net Sales
Highest at SEK 7,842 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (SEK MM)
Pre-Tax Profit
At SEK 1,778 MM has Grown at 72.45%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (SEK MM)
Net Profit
At SEK 1,373.42 MM has Grown at 66.43%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (SEK MM)
Depreciation
At SEK 1,256 MM has Grown at 60.61%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (SEK MM)
Here's what is not working for Swedish Orphan Biovitrum AB
Interest
At SEK 204 MM has Grown at 17.92%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (SEK MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
